Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/6/e010714corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade
by: Peng Liu, et al.
Published: (2025-06-01)

CDK2 inhibition sensitizes anthracycline-induced immunogenic cell death and enhances the efficacy of anti-PD-1 therapy
by: Yu Chen, et al.
Published: (2025-06-01)

Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy
by: Akimichi Morita, et al.
Published: (2024-07-01)

Ultrasound-activated miR-195-5p/shikonin nanobubbles remodel immunosuppressive microenvironment via immunogenic cell death to potentiate PD-1/PD-L1 blockade in hepatocellular carcinoma
by: Yandi Tan, et al.
Published: (2025-10-01)

TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing
by: Min Kyu Son, et al.
Published: (2025-07-01)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
by: Megan Schollenberger, et al.
Published: (2017-08-01)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
by: Taiki Kurino, et al.
Published: (2020-05-01)

Correction: Silver nanoparticle induced immunogenic cell death can improve immunotherapy
by: Ara Sargsian, et al.
Published: (2025-01-01)

Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models
by: Stefano Pierini, et al.
Published: (2025-03-01)

NIR-II photo-accelerated polymer nanoparticles boost tumor immunotherapy via PD-L1 silencing and immunogenic cell death
by: Tian Zhang, et al.
Published: (2025-04-01)

Tumor treating fields suppress tumor cell growth and induce immunogenic cell death biomarkers in biliary tract cancer cell lines
by: Ying Yue, et al.
Published: (2025-08-01)

Patritumab deruxtecan induces immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-12-01)

Arsenic trioxide as an inducer of immunogenic cell death
by: Oliver Kepp, et al.
Published: (2023-12-01)

DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy
by: Xin Yang, et al.
Published: (2025-07-01)

Arsenic Trioxide Enhances the Efficacy of PD‐1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway
by: Xionghui Wang, et al.
Published: (2025-06-01)

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model
by: Fentian Chen, et al.
Published: (2024-11-01)

Basic rules to respond to PD-1 blockade cancer immunotherapy
by: Antoni Ribas
Published: (2025-05-01)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
by: Yuan Li, et al.
Published: (2021-03-01)

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Published: (2021-10-01)

Datopotamab deruxtecan induces hallmarks of immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-08-01)

Photodynamic therapy augments oxaliplatin-induced immunogenic cell death in colorectal cancer
by: Xiaobo Wang, et al.
Published: (2023-09-01)

Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically ‘cold’ tumor models
by: Barry E. Kennedy, et al.
Published: (2025-01-01)

Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes.
by: Nora M Kochupurakkal, et al.
Published: (2014-01-01)

Synergistic Induction of Immunogenic Cell Death by Biomineralized Manganese and Bisphosphonates Enhances Anti-PD-L1 Therapy in Triple-Negative Breast Cancer
by: Zhang X, et al.
Published: (2025-04-01)

IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
by: Yoshiya Ohno, et al.
Published: (2025-03-01)

Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
by: In-San Kim, et al.
Published: (2024-07-01)

Correction: Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
Published: (2020-05-01)

Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer
by: Aohua Deng, et al.
Published: (2025-08-01)

Disruption of cholesterol homeostasis by antidepressants induces immunogenic cell death
by: Karla Alvarez-Valadez, et al.
Published: (2025-12-01)

Trial watch: chemotherapy-induced immunogenic cell death in oncology
by: Jenny Sprooten, et al.
Published: (2023-12-01)

IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment
by: Guangwei Jiang, et al.
Published: (2025-01-01)

Advancements in Nano-Delivery Systems for Photodynamic and Photothermal Therapy to Induce Immunogenic Cell Death in Tumor Immunotherapy
by: Zhao R, et al.
Published: (2025-06-01)

Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review
by: Xiangwei Meng, et al.
Published: (2025-07-01)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
by: Samaneh Moradi, et al.
Published: (2025-03-01)

Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD‐1/PD‐L1 Blockade in Patients With Non‐Small Cell Lung Cancer
by: Kiyoshi Takagaki, et al.
Published: (2025-05-01)

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
by: Loulieta Nazerai, et al.
Published: (2023-12-01)

Pan‐cancer analysis revealing DAAM1 as a novel predictive biomarker for PD‐1/PD‐L1 blockade in clear cell renal cell carcinoma
by: Jie Mei, et al.
Published: (2022-12-01)

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells
by: Chenyang Wang, et al.
Published: (2025-07-01)

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01)

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade
by: Daniel A. Ruiz-Torres, et al.
Published: (2024-12-01)